Regeneron reported strong Q2 2024 financial results with total revenue increasing 12% to $3.55 billion. Dupixent global net sales surged 27% to $3.56 billion, while U.S. EYLEA HD and EYLEA combined sales grew 2% to $1.53 billion. Libtayo global net sales rose 42% to $297 million.GAAP diluted EPS increased 46% to $12.41 and non-GAAP diluted EPS rose 13% to $11.56. R&D expenses grew 11% to $1.2 billion due to advancement of late-stage oncology programs. The company maintained strong profitability with a GAAP gross margin of approximately 86% on net product sales.The European Commission approved Dupixent for COPD, marking its first regulatory approval worldwide for this indication. FDA action on Dupixent for COPD is expected in Q3 2024. The company continues to advance its diverse clinical pipeline, including late-stage trials for multiple indications and earlier-stage programs in obesity and genetic hearing loss.

Regeneron reported strong Q2 2024 financial results with total revenue increasing 12% to $3.55 billion. Dupixent global net sales surged 27% to $3.56 billion, while U.S. EYLEA HD and EYLEA combined sales grew 2% to $1.53 billion. Libtayo global net sales rose 42% to $297 million.GAAP diluted EPS increased 46% to $12.41 and non-GAAP diluted EPS rose 13% to $11.56. R&D expenses grew 11% to $1.2 billion due to advancement of late-stage oncology programs. The company maintained strong profitability with a GAAP gross margin of approximately 86% on net product sales.The European Commission approved Dupixent for COPD, marking its first regulatory approval worldwide for this indication. FDA action on Dupixent for COPD is expected in Q3 2024. The company continues to advance its diverse clinical pipeline, including late-stage trials for multiple indications and earlier-stage programs in obesity and genetic hearing loss.